| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1083-8791(03)70009-3 |
| P698 | PubMed publication ID | 12652470 |
| P2093 | author name string | Thomas Braun | |
| Joseph P Uberti | |||
| Voravit Ratanatharathorn | |||
| John E Levine | |||
| Gregory Yanik | |||
| Lois Ayash | |||
| Raymond Hutchinson | |||
| Samuel M Silver | |||
| Christopher Reynolds | |||
| James L m Ferrara | |||
| P2860 | cites work | Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation | Q31828080 |
| LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation | Q36028584 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies | Q43505338 | ||
| Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. | Q43675457 | ||
| Regimen-related toxicity in patients undergoing bone marrow transplantation | Q70215525 | ||
| Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia | Q73008413 | ||
| Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies | Q73331610 | ||
| IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade | Q73497705 | ||
| Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT | Q74422560 | ||
| Mixed hematopoietic chimerism after hematopoietic stem cell allografts | Q74616585 | ||
| Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies | Q77093417 | ||
| Evaluation of mixed hematopoietic chimerism in pediatric patients with leukemia after allogeneic stem cell transplantation by quantitative PCR analysis of variable number of tandem repeat and testis determination gene | Q77628071 | ||
| Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation | Q77810550 | ||
| Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting | Q77891876 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 189-197 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy | |
| P478 | volume | 9 |
| Q37810098 | Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies |
| Q82527661 | Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta‐analysis |
| Q33737884 | Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study |
| Q34325487 | Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study |
| Q36707403 | Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation |
| Q35602633 | Emerging therapies for graft-versus-host disease |
| Q35825522 | Emerging therapies in hematopoietic stem cell transplantation |
| Q36615576 | Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease |
| Q83468020 | Graft-versus-host disease |
| Q35016985 | HDAC inhibition and graft versus host disease |
| Q36370782 | Implications of TNF-α in the pathogenesis and management of GVHD |
| Q46661656 | Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts |
| Q37364491 | Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity? |
| Q53609465 | Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. |
| Q34299445 | Oral complications of cancer and cancer therapy: from cancer treatment to survivorship |
| Q37700864 | Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease |
| Q79239990 | Recent publications in hematological oncology |
| Q37026059 | Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation |
| Q37543431 | The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease |
| Q37486793 | Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation |
Search more.